INSERM U1183, St. Eloi Hospital, and Montpellier University Medical School, Montpellier, France.
INSERM U1194 and UMS BioCampus Montpellier, Montpellier, France.
Arthritis Rheumatol. 2016 Apr;68(4):1013-25. doi: 10.1002/art.39477.
Systemic sclerosis (SSc) is a rare intractable disease with unmet medical need and fibrosis-related mortality. Absence of efficient treatments has prompted the development of novel therapeutic strategies, among which mesenchymal stem cells/stromal cells (MSCs) or progenitor stromal cells appear to be one of the most attractive options. The purpose of this study was to use the murine model of hypochlorite-induced SSc to investigate the systemic effects of MSCs on the main features of the diffuse form of the disease: skin and lung fibrosis, autoimmunity, and oxidative status.
We compared the effects of different doses of MSCs (2.5 × 10(5) , 5 × 10(5) , and 10(6) ) infused at different time points. Skin thickness was assessed during the experiment. At the time of euthanasia, biologic parameters were quantified in blood and tissues (by enzyme-linked immunosorbent assay, quantitative reverse transcription-polymerase chain reaction, assessment of collagen content). Assessments of histology and immunostaining were also performed.
A lower expression of markers of fibrosis (Col1, Col3, Tgfb1, and aSma) was observed in both skin and lung following MSC infusion, which was consistent with histologic improvement and was inversely proportional to the injected dose. Importantly, sera from treated mice exhibited lower levels of anti-Scl-70 autoantibodies and enhanced antioxidant capacity, confirming the systemic effect of MSCs. Of interest, MSC administration was efficient in both the preventive and the curative approach. We further provide evidence that MSCs exerted an antifibrotic role by normalizing extracellular matrix remodeling parameters as well as reducing proinflammatory cytokine levels and increasing antioxidant defenses.
The results of this study demonstrate the beneficial and systemic effects of MSC administration in the HOCl murine model of diffuse SSc, which is a promising finding from a clinical perspective.
系统性硬化症(SSc)是一种罕见的难治性疾病,存在未满足的医疗需求和与纤维化相关的死亡率。由于缺乏有效的治疗方法,促使人们开发新的治疗策略,其中间充质干细胞/基质细胞(MSCs)或祖细胞基质细胞似乎是最有吸引力的选择之一。本研究的目的是使用次氯酸盐诱导的 SSc 小鼠模型,研究 MSCs 对弥漫性疾病主要特征的全身作用:皮肤和肺纤维化、自身免疫和氧化状态。
我们比较了不同剂量的 MSCs(2.5×10^5、5×10^5 和 10^6)在不同时间点输注的效果。在实验过程中评估皮肤厚度。在安乐死时,通过酶联免疫吸附试验、定量逆转录聚合酶链反应、胶原含量评估来量化血液和组织中的生物学参数。还进行了组织学和免疫染色评估。
在皮肤和肺部,MSC 输注后观察到纤维化标志物(Col1、Col3、Tgfb1 和 aSma)的表达降低,这与组织学改善一致,且与注射剂量呈反比。重要的是,来自治疗小鼠的血清表现出较低水平的抗 Scl-70 自身抗体和增强的抗氧化能力,这证实了 MSCs 的全身作用。有趣的是,MSC 给药在预防和治疗方法中都有效。我们进一步提供证据表明,MSC 通过使细胞外基质重塑参数正常化以及降低促炎细胞因子水平和增加抗氧化防御来发挥抗纤维化作用。
这项研究的结果表明,在 HOCl 弥漫性 SSc 小鼠模型中,MSC 给药具有有益的全身作用,这是一个具有临床意义的发现。